Why This Fund Made a $5 Million Bet on Acadia Healthcare Despite a Flat Stock

13D Management initiated a new 294,000-share position in Acadia Healthcare, estimated at $5.32 million and worth $6.88 million at quarter-end, making ACHC a 10.7% AUM holding. The stake comes as Acadia reported Q1 revenue growth of 7.6% to $828.8 million, same-facility revenue up 7.3%, and adjusted EBITDA rising to $144.2 million from $134.2 million, with guidance raised. The transaction is a notable vote of confidence in a stock that has lagged the market over the past year but rebounded more than 60% last quarter.

Analysis

13D’s sizing tells us this is less a casual screening buy and more a conviction bet on a mean-reversion setup with operating leverage. In behavioral health, marginal utilization improvements flow quickly to EBITDA because fixed facility costs are high; if patient volume and pricing hold for another 2-3 quarters, the earnings delta can outpace revenue growth and justify a re-rating from “distressed” multiples to mid-teens EBITDA multiples.

The second-order beneficiary is the broader behavioral health complex: stronger ACHC execution can lift investor willingness to pay for similar asset-heavy, reimbursement-sensitive models that have been derated for years. That said, the real catalyst path is not just volume, but payer mix and staffing normalization; if wage inflation or denials re-accelerate, the same operating leverage works in reverse and the stock can give back a large chunk of the recent move quickly.

The market appears to be pricing in a partial turnaround, but not a clean one. That creates room for upside if guidance keeps moving up, yet the risk is that the stock becomes crowded among value/recovery buyers before the fundamental inflection is fully established. The key contrarian read: the setup is probably better than the headline implies because this is an earnings-quality story, not just a sentiment trade, but it is still vulnerable to any hiccup in admissions, reimbursement, or labor.

TWLO and PSO are useful context, not direct reads: 13D’s willingness to concentrate capital in ACHC suggests they prefer idiosyncratic, catalyst-driven dispersion over index-like exposure. For ACHC specifically, the next 1-2 quarters matter far more than the next year; if the company keeps comping at mid-single-digit revenue growth with expanding EBITDA margins, the stock can rerate meaningfully even without a “perfect” outcome.

Key Decisions for Investors

• Go long ACHC on pullbacks into the high-20s/low-30s with a 3-6 month horizon; target a re-rating if guidance is reaffirmed and EBITDA margin expansion continues. Risk: any deterioration in admissions or payer collections could force a quick multiple reset.
• Pair trade: long ACHC / short a more crowded healthcare-services laggard with weaker operating leverage over the next 2 quarters. The thesis is that ACHC’s fixed-cost leverage should translate into faster EPS revisions than the short leg.
• Buy ACHC call spreads 3-6 months out to express upside while defining downside; the best setup is a continuation of earnings revisions rather than an immediate melt-up. Use strikes that monetize a move back toward prior resistance while limiting premium at risk.
• If already long, trim into any post-earnings spike and keep a core position only if same-facility growth stays >5% and EBITDA guidance rises again. This is a rate-of-change story, so disappointment should be monetized quickly.
• Avoid chasing TWLO/PSO based on fund ownership alone; the signal in this filing is concentration in a niche operational turnaround, not a broader high-conviction macro or quality factor call.